Mersana Therapeutics Inc (NASDAQ:MRSN) Given Average Recommendation of “Buy” by Brokerages

Mersana Therapeutics Inc (NASDAQ:MRSN) has been given a consensus recommendation of “Buy” by the seven research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $9.50.

A number of analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Mersana Therapeutics in a report on Thursday, November 7th. Zacks Investment Research raised shares of Mersana Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 23rd. Finally, ValuEngine raised shares of Mersana Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

Shares of NASDAQ:MRSN opened at $2.78 on Thursday. The company’s 50 day moving average price is $1.73 and its two-hundred day moving average price is $3.26. Mersana Therapeutics has a 12-month low of $1.32 and a 12-month high of $7.65. The firm has a market cap of $99.60 million, a PE ratio of -1.00 and a beta of 1.51. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.06.

Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.02. Mersana Therapeutics had a negative net margin of 79.49% and a negative return on equity of 41.14%. The company had revenue of $0.84 million during the quarter, compared to the consensus estimate of $0.50 million. On average, research analysts expect that Mersana Therapeutics will post -0.6 EPS for the current year.

Several institutional investors have recently modified their holdings of the company. NEA Management Company LLC lifted its holdings in shares of Mersana Therapeutics by 0.6% during the 3rd quarter. NEA Management Company LLC now owns 11,963,649 shares of the company’s stock worth $18,903,000 after acquiring an additional 69,382 shares during the period. BlackRock Inc. lifted its stake in Mersana Therapeutics by 166.2% in the 2nd quarter. BlackRock Inc. now owns 2,390,463 shares of the company’s stock valued at $9,681,000 after purchasing an additional 1,492,618 shares during the last quarter. Boxer Capital LLC bought a new position in Mersana Therapeutics in the 2nd quarter valued at approximately $8,440,000. Vanguard Group Inc. lifted its stake in Mersana Therapeutics by 26.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,903,502 shares of the company’s stock valued at $7,709,000 after purchasing an additional 403,011 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Mersana Therapeutics by 52.4% in the 2nd quarter. Renaissance Technologies LLC now owns 266,020 shares of the company’s stock valued at $1,077,000 after purchasing an additional 91,500 shares during the last quarter. 83.50% of the stock is owned by institutional investors.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.

See Also: What is quantitative easing?

Analyst Recommendations for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.